Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as $7.15 and last traded at $6.9820, with a volume of 283812 shares. The stock had previously closed at $6.69.
More Achieve Life Sciences News
Here are the key news stories impacting Achieve Life Sciences this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $12 price target, well above the stock’s recent opening price near $7.03. The firm modestly improved its Q3 2026, Q4 2026 and FY2027 EPS forecasts, with expected losses narrowing to $(0.22), $(0.26) and $(0.79), respectively.
- Positive Sentiment: Shares have risen sharply over the past year—nearly tripling—reflecting investor expectations that Achieve’s smoking-cessation drug candidate can eventually support a profitable commercial business. Achieve Life Sciences stock has nearly tripled in the last year
- Positive Sentiment: HC Wainwright’s estimates still project a transition to positive earnings beginning in FY2028, reaching $0.23 per share in FY2028, $0.97 in FY2029 and $1.47 in FY2030, despite modest reductions to those forecasts.
- Neutral Sentiment: Achieve Life Sciences reported second-quarter 2026 financial results and provided business updates. The results are an important catalyst for investors evaluating clinical progress, regulatory timing and the company’s path toward commercialization. Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Negative Sentiment: HC Wainwright sharply lowered its FY2026 EPS forecast to a loss of $(1.54), from $(0.92), substantially below the consensus estimate of $(0.81). The company also recently reported quarterly EPS of $(0.80), missing the $(0.16) consensus estimate.
- Negative Sentiment: Longer-term earnings estimates were trimmed slightly: FY2028 fell to $0.23 from $0.24, FY2029 to $0.97 from $1.00, and FY2030 to $1.47 from $1.51. These revisions reinforce that profitability remains dependent on successful development and commercialization.
Wall Street Analyst Weigh In
ACHV has been the subject of several recent analyst reports. Canaccord Genuity Group set a $13.00 target price on Achieve Life Sciences and gave the company a “buy” rating in a research note on Monday, April 20th. Raymond James Financial reiterated a “strong-buy” rating and issued a $18.00 price target on shares of Achieve Life Sciences in a research note on Wednesday. Weiss Ratings raised Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. UBS Group restated a “buy” rating on shares of Achieve Life Sciences in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Achieve Life Sciences in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Achieve Life Sciences currently has an average rating of “Buy” and a consensus target price of $15.00.
Achieve Life Sciences Trading Up 5.2%
The stock has a market cap of $722.62 million, a P/E ratio of -4.54 and a beta of 2.24. The firm’s 50 day simple moving average is $6.03 and its two-hundred day simple moving average is $4.90. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.87.
Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). As a group, equities research analysts predict that Achieve Life Sciences, Inc. will post -0.81 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Achieve Life Sciences
Large investors have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences during the first quarter valued at approximately $32,000. Sender Co & Partners Inc. bought a new stake in shares of Achieve Life Sciences in the 2nd quarter worth approximately $56,000. Magnolia Capital Advisors LLC acquired a new position in Achieve Life Sciences during the 4th quarter valued at approximately $64,000. Bank of America Corp DE grew its stake in Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 9,617 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in Achieve Life Sciences during the 4th quarter worth $84,000. Institutional investors own 33.52% of the company’s stock.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.
Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.
Read More
- Five stocks we like better than Achieve Life Sciences
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
- Plug Power Charges Ahead: Margin Expansion Sparks a Rally
- Abercrombie’s Comeback Is a Work in Progress
- Roku’s Ad Business Is Growing—These 3 Stocks Could Be Next
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
